Foghorn Therapeutics Files 8-K

Ticker: FHTX · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1822462

Foghorn Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyFoghorn Therapeutics Inc. (FHTX)
Form Type8-K
Filed DateApr 9, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory

TL;DR

Foghorn Therapeutics filed an 8-K on 4/9/24 covering Reg FD, other events, and financials.

AI Summary

Foghorn Therapeutics Inc. filed an 8-K on April 9, 2024, to report on several events. The filing includes a Regulation FD Disclosure, other events, and financial statements and exhibits. The company is incorporated in Delaware and its principal executive office is located in Cambridge, MA.

Why It Matters

This 8-K filing provides updates on important company events and disclosures, which are crucial for investors to understand the latest developments at Foghorn Therapeutics.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not appear to contain significant negative news or events.

Key Numbers

  • 001-39634 — SEC File Number (Identifier for the company's filings)

Key Players & Entities

  • Foghorn Therapeutics Inc. (company) — Registrant
  • April 9, 2024 (date) — Date of earliest event reported
  • Cambridge, MA (location) — Principal executive office location
  • 0001822462 (company) — Central Index Key

FAQ

What specific events are disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text.

What are the 'Other Events' mentioned in the filing?

The filing lists 'Other Events' as an item information, but the specific nature of these events is not detailed in the provided text.

What is the significance of the 'Financial Statements and Exhibits' being filed?

This indicates that the company is providing updated financial information and supporting documents as part of this report.

Where is Foghorn Therapeutics Inc. headquartered?

Foghorn Therapeutics Inc.'s principal executive office is located at 500 Technology Square, Ste 700, Cambridge, MA 02139.

What is the company's Central Index Key (CIK)?

The Central Index Key for Foghorn Therapeutics Inc. is 0001822462.

Filing Stats: 818 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2024-04-09 16:41:57

Key Financial Figures

  • $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On April 9, 2024, Foghorn Therapeutics Inc. (the "Company") is hosting a conference call and webcast to review pipeline updates presented at the 2024 American Association for Cancer Research ("AACR") Annual Meeting. A copy of the presentation from the conference call and webcast is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Additionally, the Company is furnishing as Exhibit 99.2 to this Current Report on Form 8-K a presentation, dated April 2024, which the Company intends to use in meetings with or presentations to investors. The information in this Item 7.01 (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On April 9, 2024, the Company issued a press release announcing preclinical data for multiple programs from various poster presentations at the AACR 2024 Annual Meeting, including BRM selective inhibitor FHD-909, selective CBP degrader and selective EP300 degrader programs. A copy of the Company's press release is attached hereto as Exhibit 99.3 and is incorporated herein by reference.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements." Forward-looking statements include statements regarding the Company's clinical trials, product candidates and research efforts and other statements identified by words such as "could," "may," "might," "will," "likely," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects," "continues," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this Current Report speaks only as of the date on which it is made.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Webcast Presentation dated April 9, 2024 99.2 Investor Presentation dated April 2024 99.3 Press release issued on April 9, 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Michael LaCascia Michael J. LaCascia Chief Legal Officer Date: April 9, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.